Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Medicare may cover the implantation of a spinal cord stimulator as a therapy for chronic intractable pain. Chronic intractable pain refers to persistent pain that doesn’t respond to traditional ...

A range of spinal cord stimulators have been approved by the FDA, but none specifically for SCI patients. Abbott, Medtronic and Boston Scientific all have products indicated for chronic pain.

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.

The neuromodulation developer Saluda Medical announced that it raised $100 million to help bolster the sales of its closed-loop implant aimed at treating chronic pain. The company’s Evoke spinal ...